Status:

SUSPENDED

Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment

Lead Sponsor:

University of California, San Diego

Conditions:

Migraine

Cannabis

Eligibility:

All Genders

21-65 years

Phase:

PHASE2

Brief Summary

This pilot crossover study will evaluate 3 different potencies of inhaled cannabis (2.5%, 5%, and 10%) and inhaled placebo cannabis for the acute treatment of migraine.

Detailed Description

In this double-blind, randomized, crossover trial, subjects will treat 4 separate migraine attacks with 4 different treatments. Inhaled cannabis will be administered using a portable system. Subjects ...

Eligibility Criteria

Inclusion

  • Age ≥ 21 and ≤ 65
  • Able to communicate in English
  • Migraine, with or without aura, in its episodic or chronic manifestations, as per the International Headache Society (IHS) classification International Classification of Headache Disorders (ICHD-3) criteria (section 1.1, 1.2, 1.3).(48)
  • Ability to provide informed consent and complete website questionnaires in English
  • Agrees not to use cannabis outside of the study during participation in the study
  • Agrees not to use opioids or barbiturates during participation in the study
  • Agrees not to drive a motor vehicle within 4.5 hours following last use of inhaled cannabis during participation in the study

Exclusion

  • Positive urine drug test for THC, barbiturates, opioids, oxycodone, or methadone prior to enrollment
  • Pregnancy
  • Breastfeeding
  • Prisoner
  • Known cognitive impairment
  • Institutionalized
  • Current moderate-severe or severe depression
  • Current or past history of bipolar depression, schizophrenia, or psychosis
  • Current or past history of cannabis, alcohol, opioid, or amphetamine abuse or other substance use disorder at the discretion of the research team
  • Active pulmonary disease, class IV heart failure, cirrhosis, or other severe medical illnesses at the discretion of the research team.
  • Allergy to cannabis

Key Trial Info

Start Date :

February 15 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2024

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT05427630

Start Date

February 15 2023

End Date

June 1 2024

Last Update

April 30 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Center for Pain Medicine, UC San Diego

La Jolla, California, United States, 92037